IGHID 11417 - The Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection: Impact on the Latent HIV Reservoir and Long-Term Immunologic Effect
Phase of Trial: Phase II
Latest Information Update: 12 Apr 2018
At a glance
- Drugs Abacavir/dolutegravir/lamivudine (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms PHI 05
- 06 Apr 2018 Planned End Date changed from 1 Jan 2019 to 1 Jul 2021.
- 06 Apr 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jul 2021.
- 29 Sep 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.